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How to find early gastric cancer cells in vivo is a great challenge for the diagnosis and therapy of gastric cancer.
This study is aimed at investigating the feasibility of using fluorescent magnetic nanoparticle (FMNP)-labeled
mesenchymal stem cells (MSCs) to realize targeted imaging and hyperthermia therapy of in vivo gastric cancer. The
primary cultured mouse marrow MSCs were labeled with amino-modified FMNPs then intravenously injected into
mouse model with subcutaneous gastric tumor, and then, the in vivo distribution of FMNP-labeled MSCs was
observed by using fluorescence imaging system and magnetic resonance imaging system. After FMNP-labeled
MSCs arrived in local tumor tissues, subcutaneous tumor tissues in nude mice were treated under external
alternating magnetic field. The possible mechanism of MSCs targeting gastric cancer was investigated by using a
micro-multiwell chemotaxis chamber assay. Results show that MSCs were labeled with FMNPs efficiently and kept
stable fluorescent signal and magnetic properties within 14 days, FMNP-labeled MSCs could target and image
in vivo gastric cancer cells after being intravenously injected for 14 days, FMNP-labeled MSCs could significantly
inhibit the growth of in vivo gastric cancer because of hyperthermia effects, and CCL19/CCR7 and CXCL12/CXCR4
axis loops may play key roles in the targeting of MSCs to in vivo gastric cancer. In conclusion, FMNP-labeled MSCs
could target in vivo gastric cancer cells and have great potential in applications such as imaging, diagnosis, and
hyperthermia therapy of early gastric cancer in the near future.
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Gastric cancer is currently the second most common
cancer and third most common cause of cancer-related
death in China [1,2], and it is still the second most com-
mon cause of cancer-related death in the world [3]. Gas-
tric cancer remains difficult to cure because most
patients present with advanced disease [4]. Therefore,
how to recognize, track, and kill early gastric cancer cells* Correspondence: dxcui@sjtu.edu.cn
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in any medium, provided the original work is pis still one key scientific problem for early diagnosis and
therapy of patients with gastric cancer.
Since 1998, we have been trying to establish an early
gastric cancer prewarning system [5,6]. In order to
recognize early gastric cancer cells, we selected potential
biomarkers associated with gastric cancer, combined
nanoparticles and molecular imaging techniques, and
tried to identify early gastric cancer cells in vivo [7-15].
Although some differently expressed genes associated
with gastric cancer were identified [16,17], no gene
could be confirmed as a specific biomarker of gastric
cancer. Therefore, looking for a novel pathway to
recognize and treat early gastric cancer cells in vivo has
become our major concern.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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peutic method for cancer therapy following the oper-
ation, chemotherapy, and radiotherapy. Mesenchymal
stem cells (MSCs) are a subset of nonhematopoietic
multipotent cells found primarily within the bone mar-
row stroma. As one kind of promising seed cells on can-
cer therapy, MSCs not only have self-renewing and
mutlipotent features but can also efficiently carry and
deliver genes into a specific location [18-24], have
immunomodulatory property, and can home to the sites
of active tumorgenesis [25-28]. Therefore, it is possible
to use MSCs to target and identify gastric cancer cells
in vivo. Furthermore, the combination of nanotechnol-
ogy and MSCs exhibits great potential in the diagnosis
and therapy of early gastric cancer. Up to date, no report
fully confirms that MSCs could target imaging and treat
gastric cancer.
Herein, we labeled the mouse marrow MSCs with
amino-modified fluorescent magnetic nanoparticles
(FMNPs) and injected FMNP-labeled MSCs into the
mouse model with subcutaneous gastric cancer from the
mouse gastric cancer cell line mouse forestomach car-
cinoma (MFC) cells via the tail vein. Then, we investi-
gated the distribution and targeting ability of the labeled
MSCs in nude mice by fluorescence imaging system and
magnetic resonance imaging (MRI) system. Then, we
irradiated subcutaneous gastric cancer tissues in nude
mice by a given external magnetic field and finally
explored the possible mechanism of MSCs migrating to
in vivo gastric cancer cells. Results showed that FMNP-
labeled MSCs could target and recognize in vivo gastric
cancer cells and could inhibit the growth of gastric can-
cer cells under the given external magnetic field. There-
fore, FMNP-labeled MSCs have great potential in
applications such as targeted imaging and simultaneous
therapy of early gastric cancer in the near future.
Methods
All animal experiments (NO.SYXK2007-0025) were
approved by the Institutional Animal Care and Use
Committee of Shanghai Jiao Tong University.
Primary culture and identification of mouse MSCs
MSCs were isolated according to a protocol [29] and
were cultured with Dulbecco's modified Eagle's medium
(DMEM; Gibco, Shanghai, China) with 20% fetal bovine
serum (FBS; Hyclone, Thermo Scientific, Logan, UT,
USA), 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (Gibco) at 37 °C in a 5% CO2 incubator. MSC
medium was changed once every 2 days. In order to
identify MSCs, passage 3 MSCs were fixed with 4% par-
aformaldehyde, stained with R-phycoerythrin (PE)-con-
jugated CD90 antibody (BioLegend, San Diego, CA,
USA) and fluorescein isothiocyanate (FITC)-conjugatedCD29 antibody (BioLegend), respectively, and observed
with a laser confocal scanning microscope (Leica TCS
SP5, Leica Microsystems, Shanghai, China). Passage 4
MSCs were detached with 0.05% EDTA in 0.1% phos-
phate buffered saline (PBS) and rinsed with 0.1% PBS.
And then, PE-conjugated CD90 monoclonal antibody,
FITC-conjugated CD29 monoclonal antibody, and PE-
conjugated CD45 monoclonal antibody were respectively
added into cells with 0.1% PBS containing 0.5% BSA (pH
7.2) and incubated at 4 °C for 30 min. Cells were rinsed
in 0.1% frozen PBS and observed by a Calibur flow cyt-
ometer (Becton-Dickinson, Franklin Lakes, NJ, USA).
MSCs were further characterized by differentiation
assays. Passage 3 MSCs were seeded on the 24-well cul-
ture plates at a density of 5 × 104/well and incubated at
37 °C in an incubator with 5% CO2. After 24 h, when
the confluence of MSCs reached 80%, MSCs were cul-
tured with different kinds of differentiation medium.
Osteoblast differentiation culture medium consists of
DMEM with 0.1 μmol/L dexamethasone (Sigma-Aldrich,
Shanghai, China), 10 mmol/L β-sodium glyceropho-
sphate (Sigma), 50 μmol/L ascorbic acid (Sigma), 100 U/
L penicillin-streptomycin, and 10% FBS. Adipocyte dif-
ferentiation medium consists of DMEM with 10 mg/L
insulin (Sigma), 1 μmol/L dexamethasone, 0.5 mmol/L
3-isobutyl-1-methylxanthine (Sigma), and 100 μmol/L
indomethacin (Sigma). Chondrocyte differentiation cul-
ture medium consists of DMEM with 50 μg/mL ascorbic
acid, 40 μg/mL proline (Sigma), 1% insulin-transferrin-
selenium (Sigma), 0.1 μM dexamethasone (Sigma), and
10 ng/ml TGF-β (Sigma). Three weeks later, differen-
tiated osteoblasts were stained with alkaline phosphatase
(Sigma), differentiated adipocytes were stained with oil
red O (Sigma), and differentiated chondrocytes were
identified with toluidine blue stain (Ameresco, Solon,
OH, USA).
Preparation of FMNP-labeled MSCs
Silica-coated FMNPs were synthesized and characterized
according to our previous reports [30,31]. Ethanol
(95 mL) and 2 mL 3-aminopropyltriethoxysilane (APS)
were added to form a mixed solution and allowed to
react at room temperature for 24 h. The amino-modified
FMNPs were separated by permanent magnet and were
washed with deionized water three times then saved for
further usage. Prepared amino-modified FMNPs were
characterized by a transmission electron microscope
(TEM). The fluorescent and magnetic properties of the
amino-modified FMNPs were characterized by using the
photoluminescence (PL) spectra (Perkin Elmer LS 55
spectrofluorimeter, PerkinElmer, Waltham, MA, USA)
and superconducting quantum interference device mag-
netometer (PPMS-9 T, Quantum Design, Beijing, China).
Zeta-potential value of amino-modified FMNPs was
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ZLS, PSS, Port Richey, FL, USA). Then MSCs were trea-
ted with medium containing amino-modified FMNPs
(50 μg/mL) for 4 h. Afterward, the cells were stained
with Prussian blue and visualized under a light micro-
scope (Olympus IX71, Olympus, Shanghai, China); the
labeled MSCs were also stained with 1 mM Hoechst
33258 in PBS (pH 7.4) for 5 min, and fluorescent signal
of MSCs was observed by a laser confocal scanning
microscope with excitation wavelength of 488 nm (Leica
TCS SP5). The labeled MSCs were also embedded with
epoxy resin and made into ultra-thin slices and finally
observed with a transmission electronic microscope
(JEOL JEM2010, JEOL Co. Ltd., Shanghai, China).
In order to confirm whether the MSCs could be la-
beled up to 14 days, we collected unlabeled MSCs and
labeled MSCs at 7 and 14 days into eppendorf tubes to
perform the MR imaging. We also examined fluores-
cence signal of MSCs by a fluorescence microscope.
Cell viability assay
The effect of amino-modified FMNPs on MSCs was
evaluated by using the Cell Counting Kit-8 (CCK8)
assay. MSCs in 96-well plates (5,000 cells per well) were
incubated with MSC medium containing 50 μg/mL of
amino-modified FMNPs for 4 h at 37 °C. After replacing
with fresh medium, the MSCs continued to culture for 1
to 7 days. The OD values of the cells were measured by
using the Multiskan mircoplate reader (Thermo MK3,
Thermo Scientific) according to the protocol of the
CCK8 assay kit, and the survival rate of the cells was cal-
culated according to the following equation: Cell viabil-
ity (%) = optical density (OD) of the treated cells/OD of
the untreated cells × 100.
Fluorescence imaging and MRI of gastric cancer cells
in vivo
All animal experiments complied with the local ethics
committee. MFC cells (5 × 106) were injected subcutane-
ously into the right fore of the nude mice ages 6 to
8 weeks old. When tumors grew to a diameter of ap-
proximately 5 mm, 5 × 106 MSCs labeled with FMNPs
were intravenously injected into the mouse models with
gastric cancer (n= 3) via the tail vein. In the control ex-
periment, FMNPs were intravenously injected into nude
mouse models (n= 3) loaded with gastric cancer. These
mice were imaged at 7 and 14 days post-injection by
using IVIS Lumina imaging system (Xenogen (Caliper
Life Sciences), Hopkinton, MA, USA), and MR imaging
was performed at 3, 7, 10, and 14 days after post-
injection by using GE HDX 3.0 T MR imaging instru-
ment (GE Healthcare, Chalfont St. Giles, UK). The fluor-
escence signals were acquired at a lateral position on the
condition of 465-nm excitation filter and DsRedemission filter. Magnetic resonance signals were
obtained with coronal and transected T2-weighted spin
echo pulse sequences, and the following imaging para-
meters were used: TR= 2,500 ms, TE = 80 to approxi-
mately 90 ms, FOV= 40 mm, NEX= 2, and slice
thickness = 2.0 mm. Then, these mice were killed. Then
major organs, such as the liver, heart, lung, brain, and
kidney and the tumor, were collected to perform further
fluorescence imaging observation.
Immunofluorescence assay, Prussian blue staining, and
ICP-MS analysis of major organs
Gastric cancer tissues were harvested, embedded in OCT
reagent, and cryosectioned at −20 °C by a cryostat
(CM1900, Leica). Twenty micrometer-thick sections from
representative areas were directly stained with 1 μg/mL
PE-conjugated CD90 antibody for 20 min at room
temperature; then, the specimen were rinsed with 0.1%
PBS and examined by a fluorescence microscope (Olym-
pus IX71). Tumor specimen intravenously injected
FMNPs were used as the negative control. The slices were
also stained with Prussian blue and nuclear fast red and
visualized under a light microscope (Olympus IX71).
The iron content of gastric cancer tissues with FMNP-
labeled MSCs were quantitatively detected by inductively
coupled plasma mass spectrometry system (ICP-MS;
Thermo Elemental X7, Thermo Scientific). Major organs
such as the liver, heart, lung, kidney, and brain and the
tumor were excised from the mice, cut into small pieces,
weighed separately, and digested by nitric acid (67%,
ultrapure reagent grade) and hydrogen peroxide (30%,
ultrapure reagent grade). Then, the iron contents in
these samples were quantified by ICP-MS.
Hyperthermia therapy for nude mice with gastric cancer
cells
Twenty nude mice loaded with gastric cancer were ran-
domly divided into three groups: test group (10 mice,
5 × 106 FMNP-labeled MSCs cells plus external magnetic
fields), control group I (10 mice, 5 × 106 FMNP-labeled
MSCs cells ), and control group II (10 mice, FMNPs plus
external magnetic fields). When the tumor size reached
about 5 mm in diameter, nude mice were injected with
FMNP-labeled MSCs and FMNPs via the tail vein, re-
spectively. At 7 days post-injection, the mice in the test
group and control group II were put under external alter-
nating magnetic field with 63 kHz and 7 kA/m for 4 min
[32] once a week for 1 month. The tumor sizes in the test
group and control groups were measured every week.
Analysis of chemokine receptors in MSC cells and
chemokine in MFC cells
MSCs with positive CXCR4 and CCR7 were accounted
by flow cytometer. FITC-conjugated CXCR4 antibody
Figure 1 Morphology and immunophenotypic characterization of MSCs. (A) The fibroblastic morphology of passage 3 MSCs
(magnification =×100); (B) MSCs stained with FITC-conjugated CD29 antibody (×200); (C) MSCs stained with PE-conjugated CD90 antibody (×200);
(D), (E), and (F) MSCs analyzed by FACS for the positive expression of CD29 (D) and CD90 (E) and negative expression of CD45 (F); (G)
Differentiated osteoblasts tested with alkaline phosphatase staining (×100); (H) Differentiated adipocytes characterized by oil red O staining
(×100); (I) Differentiated chondrocytes verified by toluidine blue staining (×100).
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Legend) were used to sort for MSCs with CXCR4- and
CCR7-positive cells. The amounts of CXCL12 and
CCL19 in the supernatants of MFC cells were examined
by commercial enzyme-linked immunosorbent assay kits
(R & D System, Shanghai, China). The migration ability
of MSCs was evaluated by using a 48-well modified Boy-
den chamber [33-35]. The polycarbonate filter (12-μm
pore size, CN110416, Neuroprobe, Bethesda, MD, USA)
was pre-coated with 5 μg/mL fibronectin (Sigma). MSCs
were resuspended at 5 × 105/mL in the medium supple-
mented with 10% FBS and seeded in the upper chamber.
Recombinant CXC ligand 12 (CXCL12; R&D System)
and CCL19 (Peprotech, Rocky Hill, NJ, USA) were used
as chemoattractants in the lower compartment. The
chambers were incubated overnight at 37 °C. Results
were expressed as the mean number of net migratedcells over control cells (basal migration without chemo-
tactic stimulus), counted in ten microscope fields at
high-power magnification (×1,000). Each experiment
was performed in triplicate.
Statistical analysis
All data are presented in this paper as mean result ± SD.
Statistical differences were evaluated using the t test and
considered significant at P< 0.05 level. All data in this
article were obtained from three independent
experiments.
Results and discussion
Identification of cultured MSCs
Mouse marrow MSCs were collected, cultured, and pas-
saged for three passages and then identified by morph-
ology. As shown in Figure 1a, MSCs grew out fibroblast-
Figure 2 Characterization of FMNPs. (A) TEM image of amino-modified FMNPs; (B) PL intensity of amino-modified FMNPs; (C) Magnetic
intensity curve of amino-modified FMNPs; (D) Zeta-potential of FMNPs with amino group and Si-O group.
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tic biomarkers, such as positively expressing adhesion
molecules and stromal cell markers CD29 and CD90,
and negatively expressing hematopoietic stem cell mar-
ker CD45. As shown in Figure 1b,c, immunofluores-
cence staining results showed that passage 3 MSCs
positively expressed CD29 and CD90 antigens. FACS
results showed that the expression rate of CD29 and
CD90 in passage 4 MSCs were respectively 71.38% (Fig-
ure 1d) and 89.48% (Figure 1e), and the expression rate
of CD45 was 0.35% (Figure 1f ). MSC differentiation
results showed that induced osteoblasts positively
expressed alkaline phosphatase as shown in Figure 1g.
The induced adipocytes had abundant intracellular oil-
red-O-stained fat droplets as shown in Figure 1h. The
differentiated chondrocytes formed a multilayered,
matrix-rich morphology, and the extracellular matrix
presented an aubergine color after being stained with
toluidine blue as shown in Figure 1i. The above-
mentioned results fully confirmed that prepared MSCs
were multipotent stem cells.
Characterization of FMNPs
The prepared FMNPs were encapsulated with CdTe
quantum dots and Fe3O4 magnetic nanoparticles andmodified with APS. Figure 2a is the TEM image of
amino-modified FMNPs with the average diameter of
50 nm. Figure 2b shows the PL spectra of amino-
modified FMNPs whose emission wavelength was
585 nm, and the inset is the fluorescent image of the
prepared amino-modified FMNPs. Figure 2c shows that
the prepared amino-modified FMNPs were superpara-
magnetic nanoparticles composed of Fe3O4 at room
temperature with a saturation magnetization (Ms) value
of 3.2 emug−1. Figure 2d shows that prepared FMNPs
had negative zeta-potential value of −30.80 mV, and
amino-modified FMNPs had a positive zeta-potential
value of 32.25 mV.
Evaluation of FMNP-labeled MSCs
Cell membrane is negatively charged with phospholipid
bilayer, and FMNPs with positive surface charges
attached to the surface of the MSCs via electrostatic ad-
sorption with higher efficiency compared with FMNPs
with negative surface charges. As a result, amino-
modified FMNPs were attached to and entered into
in vivo MSCs, as shown in Figure 3a; fluorescent micro-
scope images showed that amino-modified FMNPs
located inside the cytoplasm of MSCs and emitted red
fluorescence around the nucleus. Prussian blue staining
Figure 3 Evaluation of FMNP-labeled MSCs. (A) Cell nucleuses and FMNPs were visible in the MSCs by fluorescent microscope observation
(×200); (B) FMNP-labeled MSCs were detected by using Prussian blue staining (×100); (C) Unlabeled MSCs were detected by using Prussian blue
staining (×100); (D) The TEM image of unlabeled MSCs. (E) The TEM image of FMNP-labeled MSCs illustrates that amino-modified FMNPs were
randomly distributed in the cytoplasm of MSCs (×6,000). (F) The magnification image of FMNPs distributed in the cytoplasm of MSCs (×12,000).
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the cytoplasm of FMNP-labeled MSCs (Figure 3c) and
no blue signal was detected in unlabeled MSCs
(Figure 3b). Furthermore, TEM results confirmed that
FMNPs located inside MSCs (Figure 3e,f ) and theFigure 4 Label stability of the FMNP-labeled MSCs. (A) MR imaging of
images of FMNP-labeled MSCs at 7 and 14 days (×200).labeled MSCs had a distinct appearance compared to
the unlabeled MSCs as shown in Figure 3d.
In order to confirm that FMNP-labeled MSCs have
stable fluorescent signal and magnetic resonance perfor-
mances up to 14 days, unlabeled MSCs and FMNP-FMNP-labeled MSCs at 7 and 14 days. (B) Fluorescent microscope
Figure 5 Effects of amino-modified FMNPs on MSCs. The survival
rates of MSCs after being labeled with FMNPs keep increasing from
day 1 to day 7. Mean values ± standard deviation of independent
experiments are shown. Asterisk represents P< 0.05
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cent microscope and MR imaging system at 7 and
14 days, as shown in Figure 4a. FMNP-labeled MSCs
emitted red strong fluorescence signal in the cytoplasm
compared to the unlabeled MSCs; the labeled MSCs at 7
and 14 days had stable fluorescence signal, and no fluor-
escence quenching was observed, similar to other
reports [36,37]. The similar results were exhibited in the
MR images as shown in Figure 4b. Labeled MSCs had
higher magnetic resonance signals than unlabeled MSCs,
and labeled MSCs at 7 and 14 days still had similar mag-
netic resonance intensity. These results showed that la-
beled MSCs kept labeled status up to 14 days.Figure 6 Fluorescent imaging of FMNP-labeled MSCs targeting gastri
tumor sites of the mice in the test group had fluorescent signals after post
sites of the mice in the control group had no fluorescent signal after post-
of major organs show that no signal was detected in the tumor and organ
detected in the tumor tissues of the test group (right).Cytotoxicity of amino-modified FMNPs
As shown in Figure 5, amino-modified FMNPs under
the dose of 50 μg/mL did not exhibit obvious cytotox-
icity to MSCs, and the survival rate of MSCs kept in-
creasing within 7 days; no statistical difference existed
between FMNP-labeled MSCs and pure MSCs (P
< 0.05). This result was similar to our previous report
[38], which implied that amino-modified FMNPs had
good biocompatibility to MSCs within the dose of
50 μg/mL and to nude mouse within the dose of 2 mg/
Kg body weight within 30 days.FMNP-labeled MSCs for targeted imaging of gastric
cancer cells in vivo
The nude mouse models loaded with gastric cancer tis-
sue with a diameter of approximately 5 mm were suc-
cessfully prepared. The FMNP-labeled MSCs were
intravenously injected into gastric cancer mouse models
their distribution in the whole body was monitored for
14 days post-injection by using IVIS fluorescence im-
aging system and MRI instrument. As depicted in
Figure 6a, no signal was detected in the tumor tissues in
the control group (left), while the fluorescence signals
were clearly detected in tumor tissue in the test group
(right), and the fluorescent signals in tumor tissues grad-
ually increased from day 7 to 14 post-injection. At day
14 post-injection, major organs, such as the lungs, kid-
neys, hearts, livers, and brains, and the tumor tissues
were collected from euthanatized mice and imaged by
using IVIS fluorescence imaging system. Tumor tissues
in the test group had remarkably fluorescent signals
compared to those in the control group, as shown inc cancer cells in vivo. (A) The in vivo fluorescent images show that
-injection of FMNP-labeled MSCs at 7 and 14 days (right), and tumor
injection of FMNPs at 7 and 14 days (left). (B) The fluorescent imaging
s of the control group (left), and obviously fluorescent signals were
Figure 7 MR imaging of FMNP-labeled MSCs targeting gastric cancer cells. The coronal and transected images of MRI show that MSCs
firstly presented in the tumor tissue at 7 days post-injection and then gradually accumulated in the tumor tissue and reached peak value at
14 days post-injection.
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detected in the heart, lung, kidney, brain, and liver.
Furthermore, the targeting ability of labeled MSCs in
the gastric cancer mouse models were monitored by MR
imaging system at 3, 7, 10, and 14 days post-injection, as
shown in Figure 7; the coronal and transected images of
the MRI showed that MSCs firstly presented in the
tumor tissue at day 7 post-injection and then gradually
accumulated in the tumor tissue and reached peak value
at day 14 post-injection. Actually, the migration of MSCs
to the tumor is a gradual course; MSCs preferentially
migrated to the tumor area and released abundant che-
mokines into microenvironment and then accumulated
around the tumors by EPR. The significant magnetic res-
onance signals from the surrounding of the tumors were
also observed at 7 days post-injection, and the magnetic
resonance signals inside the tumors were gradually
increased at 14 days post-injection. The above-
mentioned results fully demonstrate that FMNP-labeled
MSCs could target and migrate to the gastric cancer
cells in vivo.
Immunofluorescence staining, Prussian blue staining, and
ICP-MS analysis of major organs
In order to further confirm the FMNP-labeled MSCs
located in the tumor tissue, immunofluorescence staining
and Prussian blue staining of the tumor tissues were per-
formed. The tumor tissues were collected, and ultra-thin
tumor slices were prepared and stained with PE-
conjugated anti-CD90 antibody. As shown in Figure 8a,
the tumor tissues in the test group had distinct red fluor-
escent signals; conversely, the tumor tissues in the controlgroup had no fluorescent signal. The prepared ultra-thin
tumor slices were also treated with Prussian blue staining
to validate the labeled MSCs distributed in the tumor tis-
sues, as shown in Figure 8b; tumor tissues in the test
group had significant blue iron particles, and the tumor
tissues in the control group had no blue signal. These
results fully indicate that the FMNP-labeled MSCs could
target the gastric cancer tissues.
The distribution of labeled MSCs in vivo was also ana-
lyzed by ICP-MS. The concentration of iron in the
tumor tissues of the test group (8.4 μg/mg) was signifi-
cantly higher than that of the control group (2.7 μg/mg),
as shown in Figure 8c. For other organs such as the liver,
heart, lung, brain, and kidney, no statistical difference
was observed between the test group and the control
group (P< 0.05). These data also demonstrate that
FMNP-labeled MSCs mainly distribute in the site of gas-
tric cancer tissues in vivo.
Hyperthermia therapy of subcutaneous tumors
The nude mice loaded with gastric cancer in the test
group were injected with FMNP-labeled MSCs, the nude
mice loaded with gastric cancer in control group I were
also injected with FMNP-labeled MSCs, and the nude
mice loaded with gastric cancer in control group II were
injected with FMNPs. At 7 days post-injection, the nude
mice in the test group and control group II were treated
with alternating magnetic field with 63 kHz and 7 kA/m
for 4 min once a week for 1 month, and the nude mice
in control group I were not treated. Figure 9a shows the
time-temperature curves of FMNPs and FMNP-labeled
MSCs under alternating magnetic field irradiation, which
Figure 8 Ex vivo analysis of major tissues. (A) Immunofluorescence-staining analysis shows that the tumor tissue slices in the test group had
obvious fluorescent signals and that there was no fluorescent signal in the control group. (B) Prussian blue-staining results show that the tumor
tissue slices in the test group had blue iron particles, and that there was no iron particle in the control group. (C) The ICP-MS results show that
FMNPs were mainly distributed in the tumor tissues of the test group.
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MSCs is lower than that of FMNPs. As shown in Fig-
ure 9b, the average size of tumors in the test group is
significantly smaller than in control group I and control
group II (P< 0.05), and the average size of tumor in
control group I was bigger than in control group II,
which demonstrates that FMNP-labeled MSCs may not
inhibit the growth of tumor. However, FMNP-labeled
MSCs combined with alternating external magnetic field
could markedly inhibit the growth of tumor cells in vivo.
Possible molecular mechanism
Since chemokines and chemokine receptors are involved
in chemotaxis and cell migration, in order to investigate
the mechanism of FMNP-labeled MSCs migrating togastric cancer sites in vivo, we analyzed the chemokine
receptors' expression levels in MSCs and measured the
chemokine levels in the supernatant of the MFC cells.
As shown in Figure 10a, flow cytometer analysis showed
that 91.29% of mES cells exhibited positive CXCR4 and
that 72.43% of mES cells exhibited positive CCR7. ELISA
results showed that CXCL12 and CCL19 levels in the
supernatant of MFC cells were 13.2 ± 1.8 ng/mL and
5.5 ± 0.7 ng/mL, respectively. Then, the migration ability
of MSCs in response to chemotactic signals was investi-
gated by using a micro-multiwell chemotaxis chamber
assay. Results show that MSCs migrated to different
concentrations of CXCL12 and CCL19 in a dose-
dependent manner, as shown in Figure 10b. Therefore,
in the course of MSCs targeting gastric cancer cells
Figure 9 Effects of alternating magnetic field on the gastric tumor size. (A) Time-temperature curve of FMNP-labeled MSCs under an
alternating magnetic field with 63 kHz and 7kA/m; (B) The growth of tumors was inhibited under hyperthermia therapy.
Ruan et al. Nanoscale Research Letters 2012, 7:309 Page 10 of 12
http://www.nanoscalereslett.com/content/7/1/309in vivo, the loops such as CXCL12-CXCR4 and CCL19-
CCR7 may take great effects. Although our primary
studies show that mouse MSCs can target in vivo mouse
gastric cancer cells and also confirm that CXCL12-
CXCR4 and CCL19-CCR7 loops were involved in the
course, the concrete mechanism of the mouse MSCs tar-
geting gastric cancer cells in vivo is still under
investigation.
Conclusion
In conclusion, this study clearly confirms that FMNP-
labeled MSCs could target gastric cancer cells in vivo
and could be used as dual-modality contrast agents for
in vivo gastric cancer's fluorescent imaging and magnetic
resonance imaging. The prepared FMNPs had good bio-
compatibility and could be used for hyperthermiaFigure 10 Analysis of chemokine receptors and chemotaxis. (A) The e
The migration of MSCs to different concentrations of CXCL12 and CCL19 wtherapy of gastric cancer in vivo under a given external
magnetic field. Regarding the mechanism of FMNP-
labeled MSCs recognizing in vivo gastric cancer cells, we
consider that CCL19/CCR7 and CXCL12/CXCR4 axis
loops may be involved in this course. The concrete
mechanism is under investigation. Therefore, FMNP-
labeled MSCs have great potentials in applications such
as detection, fluorescent imaging, magnetic resonance
imaging, and simultaneous hyperthermia therapy for
early gastric cancer in the near future.
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